Abstract：
Preterm birth (PTB) is defined as birth before 37 completed weeks of gestation. It is generally agreed, preterm delivery is the most important obstetrical complication leading to perinatal morbidity and mortality. The aim of this study is to assess the prevalence of progesterone prescription, the route of administration, the prevalence of PTB, and the route of delivery as well as to look at the rates of PTB among those who received progesterone and those who did not. An observational cross-sectional study among postpartum women was done between April and September 2023. A convenience sample of 300 women were interviewed at maternity hospitals and primary health centers in Duhok. A survey of postpartum women up to 1 year postpartum was completed. Patients were questioned about basic pregnancy information, risk factors, and complications, as well as the use (if any) of progesterone. The preterm birth (<37 week) rate is 12%. From the 300 patients in the sample, 114 (38%) women had history of single or multiple progesterone therapies. The most common single route of progesterone therapy was the parenteral route (29.8%), but more patients received progesterone via multiple routes (32.4%). Pre-term birth was reported in 19 women who received progesterone treatment compared to 17 women among those who did not receive progesterone treatment. No statistically significant variations were found between the two groups (P=0.08). There were no statistically significant differences in prevalence of PTB or route of delivery between women who received progesterone supplementation and those who did not receive progesterone (P=0.08 and P= 0.14 respectively). Prior research has shown that the clearest evidence of benefit for progesterone in pregnancy is among those with short cervix. Perhaps the lack of significant difference found in this study was because of prescriptions outside of established indications. More randomized controlled trials are needed to assess the effects of progesterone supplementation during pregnancy.
摘要：
早产（PTB）定义为在妊娠37周之前出生。人们普遍同意，早产是导致围产期发病率和死亡率的最重要产科并发症。这项研究的目的是评估孕酮处方的患病率，管理的途径,PTB的患病率，和分娩途径，以及观察接受孕酮和未接受孕酮的人的PTB发生率。在2023年4月至9月之间对产后妇女进行了观察性横断面研究。在Duhok的妇产医院和初级保健中心采访了300名妇女的便利样本。完成了对产后妇女长达1年的调查。患者被问及怀孕的基本信息，危险因素，和并发症，以及黄体酮的使用（如果有的话）。早产（<37周）率为12％。从样本中的300名患者中，114名（38%）女性有单一或多种孕激素治疗史。最常见的单一途径黄体酮治疗是肠胃外途径(29.8%),但更多的患者通过多种途径接受黄体酮(32.4%)。据报道，19名接受黄体酮治疗的妇女早产，而未接受黄体酮治疗的妇女为17名。两组间差异无统计学意义(P=0.08)。接受孕酮补充的妇女与未接受孕酮补充的妇女之间的PTB患病率或分娩途径差异无统计学意义（分别为P=0.08和P=0.14）。先前的研究表明，孕酮在怀孕期间受益的最明显证据是子宫颈短的人。也许在这项研究中发现缺乏显着差异是因为在既定适应症之外的处方。需要更多的随机对照试验来评估怀孕期间补充孕酮的效果。
